Harrow relaunches triamcinolone acetonide injectable suspension
Marketed as Triesence, it is a preservative-free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.
(Image credit: AdobeStock/MakoPoko)
Harrow announced the relaunch of triamcinolone acetonide injectable suspension (Triesence) 40 mg/mL, a preservative‑free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.
According to the company, triamcinolone acetonide injectable suspension is a single-use vial of 40 milligrams or 40 units based on the HCPCS descriptor.1
Mark L. Baum, chairman and CEO of Harrow, said the company was pleased to have brought triamcinolone acetonide injectable suspension to the US market.
“Accomplishing this required rebuilding the entire Triesence supply chain and involved a global collaboration between Harrow and technical experts from our partners around the world,” Braun said in a news release. “We are grateful for this team’s dedication and commitment, without which we would not have achieved this success."
Rishi Singh, MD, an ophthalmologist and vitreoretinal surgeon of Cleveland Clinic Florida, noted in a news release that an FDA-approved, preservative-free corticosteroid is critical for office-based and surgical procedures.
“Triesence is a pharmaceutically elegant injectable suspension that appears as a white backdrop against the back of the retina, enabling a higher degree of visibility of the vitreous and pathologic membranes during vitrectomy,” he said in the news release. “It has long been a trusted, indispensable resource, and its absence has left many ophthalmologists and retina specialists without a reliable alternative.”
Moreover, Singh noted the relaunch of Triesence after more than 5 years on the FDA Drug Shortage List and 2 years of inventory depletion, brings much-needed relief for both eyecare professionals and their patients.
“During its absence, many were forced to adapt with less ideal, off-label solutions such as modifying preserved Kenalog-40, which posed potential risks,” he said. “Now that Triesence is back, we can confidently provide safer, more effective treatment, improving surgical outcomes and patient care."
John W. Kitchens, MD, an ophthalmologist and vitreoretinal surgeon with Retina Associates of Kentucky, said triamcinolone acetonide injectable suspension is “a potent anti-inflammatory properties also play a critical role in managing severe ocular inflammatory conditions that don’t respond to topical treatments, reducing swelling, pain, and the risk of long-term damage.”
“I couldn't be more excited to have this vital tool back in my armamentarium, ensuring the best possible care for patients,” he concluded.
Reference:
Wire B. Harrow Relaunches TRIESENCE®. Yahoo.com. Published October 3, 2024. Accessed October 3, 2024. https://finance.yahoo.com/news/harrow-relaunches-triesence-110000615.html
